Physician profile
Michael Long
NPI 1386676542
$4,680.64
in general payments reported to CMS, 2019-2025
24 companies · $51.98 in 2025
The $51.98 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $734 · 2021: $928 · 2022: $1,299 · 2023: $674 · 2024: $161 · 2025: $51.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,808.84 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $496.66 | 2019-2023 | |
| Janssen Biotech, INC. | $341.00 | 2019-2021 | |
| Amgen INC. | $337.81 | 2021-2023 | Otezla |
| Leo Pharma INC. | $305.12 | 2022-2024 | Adbry |
| Lilly USA, LLC | $304.53 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $274.63 | 2019-2023 | Dupixent |
| Genzyme Corporation | $231.98 | 2019-2021 | |
| Pfizer INC. | $114.61 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $79.85 | 2022-2023 | Sotyktu |
| Dermavant Sciences, INC. | $58.70 | 2023 | Vtama |
| Incyte Corporation | $54.92 | 2022-2025 | Opzelura |
| Journey Medical Corporation | $49.99 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.63 | 2021-2023 | Trulance, Xifaxan |
| Arcutis Biotherapeutics, INC. | $27.79 | 2024 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $27.44 | 2020-2021 | |
| Ge Healthcare | $24.14 | 2025 | |
| Sun Pharmaceutical Industries INC. | $18.85 | 2020 | |
| Mayne Pharma Commercial LLC | $16.48 | 2021 | |
| Merck Sharp & Dohme LLC | $15.43 | 2019 | |
| Dermira, INC. | $15.29 | 2019 | |
| Bioventus LLC | $13.34 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.18 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.